Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03940833|
Recruitment Status : Unknown
Verified May 2019 by Asclepius Technology Company Group (Suzhou) Co., Ltd..
Recruitment status was: Recruiting
First Posted : May 7, 2019
Last Update Posted : May 7, 2019
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Biological: BCMA CAR-NK 92 cells||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM|
|Estimated Study Start Date :||May 2019|
|Estimated Primary Completion Date :||May 2021|
|Estimated Study Completion Date :||May 2022|
Experimental: anti-tumor response of BCMA CAR-NK-92
Patients with relapsed and refractory MM of BCMA expression will be treated with BCMA CAR-NK 92 cells.
Biological: BCMA CAR-NK 92 cells
The subject will be observed for any side effects during this time and all the adverse events will be recorded.
- Occurrence of treatment related adverse events as assessed by CTCAE v4.03 [ Time Frame: 1 year ]Defined as >= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03940833
|Contact: Guangfu Li||+86 firstname.lastname@example.org|
|Contact: Xianfeng Feng||+86 email@example.com|
|Department of Hematology, Wuxi People's Hospital, Nanjing Medical University||Recruiting|
|Wuxi, Jiangsu, China, 214000|
|Contact: Xin Zhou, PhD firstname.lastname@example.org|